TY - JOUR
T1 - Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer
AU - Dinh, Tru Khang T.
AU - Mitin, Timur
AU - Bagshaw, Hilary P.
AU - Hoffman, Karen E.
AU - Hwang, Clara
AU - Jeffrey Karnes, R.
AU - Kishan, Amar U.
AU - Liauw, Stanley L.
AU - Lloyd, Shane
AU - Potters, Louis
AU - Showalter, Timothy N.
AU - Taira, Al V.
AU - Vapiwala, Neha
AU - Zaorsky, Nicholas G.
AU - D'Amico, Anthony V.
AU - Nguyen, Paul L.
AU - Davis, Brian J.
N1 - Funding Information:
Disclosures: T.M. reports royalties from UpToDate, research grant from Novocure, honorarium and travel compensation from Novocure, AstraZeneca and Janssen. A.U.K. reports honoraria from Varian Medical Systems, Inc. N.G.Z. is supported by the National Institutes of Health LRP 1 L30 CA231572-01 and ViewRay, Inc, consulting fees from Varian Medical Systems, Inc and Intelligent Automation, Inc., research funding from ViewRay, Inc, and serving on an advisory board for Janssen, the American Cancer Society, CSDG-CCE 133738. P.N. reports consulting fees from Janssen, Ferring, Bayer, Boston Scientific, Cota, Astellas, Dendreon, and Blue Earth, and research funding from Janssen, Bayer, and Astellas. K.H. reports research funding from Varian Medical Systems and Janssen. T.N.S. reports a research grant from Varian Medical Systems.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/3/15
Y1 - 2021/3/15
N2 - Purpose: Definitive radiation therapy (RT), with or without concurrent chemotherapy, is an alternative to radical cystectomy for patients with localized, muscle-invasive bladder cancer (MIBC) who are either not surgical candidates or prefer organ preservation. We aim to synthesize an evidence-based guideline regarding the appropriate use of RT. Methods and Materials: We performed a Preferred Reporting Items for Systematic Reviews and Meta-analyses literature review using the PubMed and Embase databases. Based on the literature review, critical management topics were identified and reformulated into consensus questions. An expert panel was assembled to address key areas of both consensus and controversy using the modified Delphi framework. Results: A total of 761 articles were screened, of which 61 were published between 1975 and 2019 and included for full review. There were 7 well-designed studies, 20 good quality studies, 28 quality studies with design limitations, and 6 references not suited as primary evidence. Adjuvant radiation therapy after cystectomy was not included owing to lack of high-quality data or clinical use. An expert panel consisting of 14 radiation oncologists, 1 medical oncologist, and 1 urologist was assembled. We identified 4 clinical variants of MIBC: surgically fit patients who wish to pursue organ preservation, patients surgically unfit for cystectomy, patients medically unfit for cisplatin-based chemotherapy, and borderline cystectomy candidates based on age with unilateral hydronephrosis and normal renal function. We identified key areas of controversy, including use of definitive radiation therapy for patients with negative prognostic factors, appropriate radiation therapy dose, fractionation, fields and technique when used, and chemotherapy sequencing and choice of agent. Conclusions: There is limited level-one evidence to guide appropriate treatment of MIBC. Studies vary significantly with regards to patient selection, chemotherapy use, and radiation therapy technique. A consensus guideline on the appropriateness of RT for MIBC may aid practicing oncologists in bridging the gap between data and clinical practice.
AB - Purpose: Definitive radiation therapy (RT), with or without concurrent chemotherapy, is an alternative to radical cystectomy for patients with localized, muscle-invasive bladder cancer (MIBC) who are either not surgical candidates or prefer organ preservation. We aim to synthesize an evidence-based guideline regarding the appropriate use of RT. Methods and Materials: We performed a Preferred Reporting Items for Systematic Reviews and Meta-analyses literature review using the PubMed and Embase databases. Based on the literature review, critical management topics were identified and reformulated into consensus questions. An expert panel was assembled to address key areas of both consensus and controversy using the modified Delphi framework. Results: A total of 761 articles were screened, of which 61 were published between 1975 and 2019 and included for full review. There were 7 well-designed studies, 20 good quality studies, 28 quality studies with design limitations, and 6 references not suited as primary evidence. Adjuvant radiation therapy after cystectomy was not included owing to lack of high-quality data or clinical use. An expert panel consisting of 14 radiation oncologists, 1 medical oncologist, and 1 urologist was assembled. We identified 4 clinical variants of MIBC: surgically fit patients who wish to pursue organ preservation, patients surgically unfit for cystectomy, patients medically unfit for cisplatin-based chemotherapy, and borderline cystectomy candidates based on age with unilateral hydronephrosis and normal renal function. We identified key areas of controversy, including use of definitive radiation therapy for patients with negative prognostic factors, appropriate radiation therapy dose, fractionation, fields and technique when used, and chemotherapy sequencing and choice of agent. Conclusions: There is limited level-one evidence to guide appropriate treatment of MIBC. Studies vary significantly with regards to patient selection, chemotherapy use, and radiation therapy technique. A consensus guideline on the appropriateness of RT for MIBC may aid practicing oncologists in bridging the gap between data and clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85102214714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102214714&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2020.10.031
DO - 10.1016/j.ijrobp.2020.10.031
M3 - Review article
C2 - 33127490
AN - SCOPUS:85102214714
SN - 0360-3016
VL - 109
SP - 953
EP - 963
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -